AI Article Synopsis
- Nilotinib is a type of medication used to block a specific protein (BCR-ABL) involved in cancer, but it also affects how other drugs are metabolized in the body by inhibiting the enzyme CYP3A4.
- Because it can raise the levels of other drugs that are processed by CYP3A4, healthcare providers need to be cautious when prescribing these medications to patients taking nilotinib.
- After a transplant, patients treated with nilotinib require close monitoring of their drug levels to ensure safe and effective use of immunosuppressive medications.
Article Abstract
Nilotinib, a BCR-ABL tyrosine kinase inhibitor, is a known inhibitor of CYP3A4 and could increase the concentration of drugs metabolized by CYP3A4. An immunosuppressive drug for nilotinib-treated patients following transplant should be administered with careful pharmacokinetic monitoring because of its interaction with nilotinib.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412900 | PMC |
| http://dx.doi.org/10.1002/ccr3.900 | DOI Listing |
Publication Analysis
Top Keywords
drug interaction
4
interaction tacrolimus
4
tacrolimus nilotinib
4
nilotinib patient
4
patient chronic
4
chronic myeloid
4
myeloid leukemia
4
leukemia renal
4
renal transplant
4
transplant nilotinib
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!